Diabetic ketoacidosis after treatment with pembrolizumab
Journal of Clinical and Translational Endocrinology: Case Reports · 2017
DOI: 10.1016/j.jecr.2017.05.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical and Translational Endocrinology: Case Reports, 2017. Verfasst von M. Hariz. F. Abdul Aziz und 3 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibiting agents have been shown to precipitate type 1 diabetes. We report a case of acute severe diabetic ketoacidosis in a patient with no history of diabetes who developed ketoacidosis after starting anti-PD1 immunotherapy with Pembrolizumab. Key Words Immune Checkpoint inhibitors, Pembrolizumab, Diabetic Ketoacidosis, Melanoma, Programmed Cell Death receptor, Anti PD1, PD 1 Inhibitor Introduction Pembrolizumab is a monoclonal antibody mainly used in the treatment of advanced/metastatic malignant melanoma (and also historically less responsive tumour types) [1] that acts by blocking the inhibitory ligand (PDL1) of the PD1 (programmed cell death 1) receptor. Anti-PD-1 therapy has been shown to precipitate type 1 diabetes in non-obese diabetic mice models [2] and only recently has diabetic keto-acidosis (DKA) secondary to PD1 antibody use been reported in humans [3] , [4] , [5] ].
Zitieren
APA
Aziz, M. H. F. A., Fernando, I. P., Lenkanpally, A., & Fernando, D. J. (2017). Diabetic ketoacidosis after treatment with pembrolizumab. Journal of Clinical and Translational Endocrinology: Case Reports. https://doi.org/10.1016/j.jecr.2017.05.002
Vancouver
Aziz MHFA, Fernando IP, Lenkanpally A, Fernando DJ. Diabetic ketoacidosis after treatment with pembrolizumab. Journal of Clinical and Translational Endocrinology: Case Reports. 2017. doi:10.1016/j.jecr.2017.05.002
BibTeX
@article{Aziz2017,
author = {Aziz, M. Hariz. F. Abdul and Fernando, Isuru P. and Lenkanpally, Anjan and Fernando, Devaka J.S.},
title = {Diabetic ketoacidosis after treatment with pembrolizumab},
journal = {Journal of Clinical and Translational Endocrinology: Case Reports},
year = {2017},
doi = {10.1016/j.jecr.2017.05.002}
}
EUVIMED